EIPA

Item no.	HY-101840-50mg
Manufacturer	MedChem Express
CASRN	1154-25-2
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitor
Specific against	other
Purity	99.73
Citations	[1]Dai XQ, et al. Inhibition of TRPP3 channel by MK-870 and analogs. Mol Pharmacol. 2007 Dec;72(6):1576-85.\|[2]Shi H, et al. Na+/H+ Exchanger Regulates Amino Acid-Mediated Autophagy in Intestinal Epithelial Cells. Cell Physiol Biochem. 2017;42(6):2418-2429.\|[3]Zhu BY, et al. A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosis.\|[4]E V Stelmashook, et al. Acidosis and 5-(N-ethyl-N-isopropyl)amiloride (EIPA) Attenuate Zinc/Kainate Toxicity in Cultured Cerebellar Granule Neurons. Biochemistry (Mosc). 2015 Aug;80(8):1065-72. \|[5]Shigekuni Hosogi, et al. An inhibitor of Na(+)/H(+) exchanger (NHE), ethyl-isopropyl amiloride (EIPA), diminishes proliferation of MKN28 human gastric cancer cells by decreasing the cytosolic Cl(-) concentration via DIDS-sensitive pathways. Cell Physiol Biochem. 2012;30(5):1241-53.\|[6]Junji Yamashita, et al. Role of Na+/H+ exchanger in the pathogenesis of ischemic acute renal failure in mice. J Cardiovasc Pharmacol. 2007 Mar;49(3):154-60. \|[7]Fumitaka Kamachi, et al. Inhibition of lipopolysaccharide-induced prostaglandin E2 production and inflammation by the Na+/H+ exchanger inhibitors. J Pharmacol Exp Ther. 2007 Apr;321(1):345-52. ACS Appl Mater Interfaces. 2020 Oct 14;12(41):45763-45771.\|ACS Nano. 2020 Nov 24;14(11):14698-14714.\|ACS Nano. 2024 Sep 11.\|Adv Funct Mater. 2021 Apr 1.\|Adv Mater. 2025 Jan 10:e2415030.\|Adv Sci (Weinh). 2024 Nov 6:e2412014.\|Anal Chem. 2020 Jan 21;92(2):2103-2111.\|Autophagy. 2022 Aug 1;1-19.\|BBA-Gen Subjects. 2022: 130300.\|Biol Open. 2023 Oct 5:bio.060081.\|Biomacromolecules. 2021 Aug 12.\|Biomaterials. 13 January 2022, 121373.\|Bioorg Chem. 2022 Feb 12;121:105651.\|bioRxiv. 2024 Jan 11.\|Biotechnol J. 2022 Nov 2;e2200393\|BMC Plant Biol. 2025 Feb 7;25(1):159.\|Carcinogenesis. 2024 Jul 15:bgae045.\|Cell Metab. 2022 Dec 6;34(12):2018-2035.e8.\|Chem Eng J. 2024 Sep 1.\|Clin Transl Med. 2025 Jan;15(1):e70191.\|Comput Struct Biotec. 2021;19:1933-1943.\|Drug Deliv. 2021 Dec;28(1):800-813.\|Exp Hematol. 2024 Oct 1:104651.\|Genes Dev. 2021 Oct 1;35(19-20):1327-1332.\|iScience. 2023 Mar 30.\|J Biol Chem. 19 September 2022, 102511.\|J Control Release. 2022 Oct 7;351:703-712.\|J Control Release. 2023 Feb 17;355:675-684.\|J Control Release. 2024 Apr 24:370:140-151.\|J Exp Med. 2023 Mar 6;220(3):e20221316.\|J Hazard Mater. 2021 Sep 5;417:126092.\|J Nanobiotechnology. 2022 Jun 10;20(1):268.\|J Neuroinflammation. 2024 May 10;21(1):125.\|J Pathol. 2023 Jan 30. doi: 10.1002/path.6059.\|J Virol. 2021 Sep 29;JVI0134521.\|Matter. 2023 Aug 31.\|Microvasc Res. 2021, 104219.\|Nanotoxicology. 2023 Jan 26;1-18.\|Nat Commun. 2024 Jan 2;15(1):162.\|Nat Commun. 2025 Feb 4;16(1):1327.\|Nat Nanotechnol. 2024 Oct 28.\|Pharmaceutics. 2020 Feb 17;12(2):167.\|Pharmaceutics. 2024 Nov 21.\|PLoS Pathog. 2024 Nov 21;20(11):e1012681.\|Sci Adv. 2020 Aug 12;6(33):eaaz1774.\|Sci China Life Sci. 2021 May 27;1-21.\|Sci China Mater. 63, 620-628 (2020).\|Theranostics. 2022 Jan 1;12(3):1061-1073.\|Vet Res. 2023 Mar 14;54(1):24.\|Viruses. 2021 May 31;13(6):1035.\|Acta Biomater. 2023 Dec 18:S1742-7061(23)00724-9.\|Emerg Microbes Infect. 2022 Dec;11(1):1135-1144.\|J Nanobiotechnology. 2022 Jul 20;20(1):340.\|Mol Pharm. 2021 Sep 7.
Smiles	O=C(C1=NC(Cl)=C(N(CC)C(C)C)N=C1N)NC(N)=N
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	L593754,MH 12-43,Ethylisopropylamiloride
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Autophagy; COX; Na+/H+ Exchanger (NHE); Prostaglandin Receptor; TRP Channel
Shipping Temperature	Blue Ice
Storage Conditions	-20°C, 3 years (Powder)
Molecular Weight	299.76
Product Description	EIPA (L593754) is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA also enhances autophagy by inhibiting Na+/H+-exchanger 3 (NHE3). EIPA inhibits macropinocytosis as well. EIPA can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma[1][2][3][4][5][6][7].
Manufacturer - Research Area	Cancer; Inflammation/Immunology
Solubility	DMSO: 100 mg/mL (ultrasonic)\|H2O: < 0.1 mg/mL (ultrasonic)
Manufacturer - Pathway	Autophagy; GPCR/G Protein; Immunology/Inflammation; Membrane Transporter/Ion Channel; Neuronal Signaling
Isoform	COX-2
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-101840-50mg-safety-datasheet.pdf